Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Musculoskeletal
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
FDA continues "safety review" of potential link between bisphosphonates and fractures
11 March 2010
The US FDA has announced an "ongoing safety review" of oral bisphosphosphonates to see if they are potentially linked to atypical subtrochanteric femur fractures, or fractures in the bone just below the hip joint. For the data reviewed to date, ...
Amgen's Prolia beats Zometa in final Phase III bone metastases trial
09 February 2010
Amgen's Prolia (denosumab) was superior to Novartis's bisphosphonate Zometa (zoledronic acid) in delaying bone complications in prostate cancer patients with bone metastases, show top-line Phase III data. Before the data was announced, Jefferies ...
Cartilage replacement company spun out from Cardiff University
08 February 2010
Fusion IP, a UK-based university technology commercialisation company, has created a new spin-out company, Progenteq, under its exclusive agreement with Cardiff University. Progenteq is at the early stages of developing a novel cartilage replacement ...
GSK launches new rare disease research unit
05 February 2010
GlaxoSmithKline has formed a new standalone unit to develop treatments for rare diseases. GSK's president of Asia Pacific and chairman of Japan Marc Dunoyer will lead the new operation and will work closely with the company's senior vice-president ...
First drug for Dupuytren's contracture approved by US FDA
03 February 2010
Auxilium Pharmaceuticals ' novel therapy Xiaflex (collagenase clostridium histolyticum) has become the first US-approved drug to treat a potentially debilitating hand condition known as Dupuytren's contracture. The launch of Xiaflex is planned for ...
 
2010 Scrip 100 - US therapeutic NME and new biological approvals
09 December 2009
US therapeutic NME and new biological approvals* Product Generic name Company Indication Approval date Afinitor everolimus Novartis advanced renal cell ...
2010 Scrip 100 - Stem cell trials, tribulations and trailblazers
09 December 2009
The prospects of true innovation have lured companies of all sizes into the stem cell space. The strategies being implemented by research groups are diverse and colourful, yet the regulatory terrain ...
Market Insight - Alliances boost drug delivery as M&A and financing stall
29 October 2009
Activity in the drug delivery sector has been geared towards alliances in 2009, says Phil Greenfield. The drug delivery sector was worth an estimated $50 billion in 2008 and is now a major sector of ...
 
Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
15 June 2009
In escaping the sweltering heat of America's south, Scrip's US reporter Christopher Spillane meets Amgen's chief medical officer, Dr Sean Harper , who coolly explains how the firm plans to negotiate ...
 
An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution
01 July 2008
Background: Osteoarthritis (OA) is the most common chronic degenerative disease, which is characterised by the destruction of the articular cartilage and subchondral bone. The current treatment of OA ...
Emerging drugs for rheumatoid arthritis
01 March 2008
Background: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic, autoimmune disease characterized by symmetric arthritis of diarhthrodial joints leading to progressive erosion of cartilage ...
Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair
01 March 2008
Background: Mesenchymal stem cells (MSC) are multipotent cells with the ability to differentiate into mesenchyme-derived cells including osteoblasts and chondrocytes. Objective: To provide an ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm